New england journal of medicine publishes positive results from phase 2 willow study of brensocatib in patients with non-cystic fibrosis bronchiectasis

Bridgewater, n.j., sept. 7, 2020 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that final results from the phase 2 willow study of brensocatib in.
INSM Ratings Summary
INSM Quant Ranking